Optrex Hayfever Relief (Sodium Cromoglicate)

Sodium cromoglicate, the active ingredient in Optrex Hayfever Relief, is a mast cell stabilizer presented as an ocular solution for eye use. It relieves allergic conjunctivitis and hay‑fever eye symptoms in adults and children.

GNH USA supplies Optrex Hayfever Relief as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Sodium cromoglicate acts on ocular allergic pathways to control inflammation and histamine release.

Allergic conjunctivitis: reduces itching, redness, and tearing associated with eye allergies. Hay‑fever eye symptoms: alleviates seasonal ocular discomfort such as itching and watery eyes. Seasonal ocular allergy: helps prevent flare‑ups during pollen seasons.

Sodium cromoglicate is generally well tolerated, but ocular preparations can cause local reactions.

Common Side Effects: - Transient eye irritation or stinging on instillation - Mild blurred vision lasting a few minutes - Burning sensation or foreign‑body feeling - Temporary increased tearing - Mild headache

Serious or Rare Side Effects: - Allergic reaction with swelling of the eyelid or conjunctiva - Severe eye inflammation or keratitis - Corneal ulceration - Anaphylactic response (extremely rare)

Before using Optrex Hayfever Relief, consider the following safety points.

Hypersensitivity: avoid if you have known allergy to sodium cromoglicate or any excipients. Contact lens wearers: remove lenses before instillation and wait several minutes before reinserting. Concurrent ocular meds: consult a healthcare professional before combining with other eye drops. Pediatric use: follow prescriber guidance for children under the recommended age. Pregnancy and breastfeeding: discuss with a physician as safety data are limited. Store below 25°C: keep in the original container, protect from light and moisture.

Sodium cromoglicate may interact with other ocular agents; monitor for additive irritation.

Major Interactions (Avoid): - Use with preservative‑containing contact lens solutions: may increase ocular irritation. - Concurrent topical corticosteroids: can heighten risk of eye surface irritation.

Moderate Interactions (Monitor Closely): - Systemic antihistamines: may alter tear film stability, watch for dryness. - Other mast‑cell stabilisers: monitor for overlapping effects. - Ocular decongestants: assess for additive vasoconstriction.